Journal of Cancer Research and Therapeutics Close
 

Table 3: First line comparative activity in terms of progression-free survival of monoclonal antibody check point inhibitors in nonsmall-cell lung cancer

Table 3: First line comparative activity in terms of progression-free survival of monoclonal antibody check point inhibitors in nonsmall-cell lung cancer